On the maraviroc pdl1 thing.I was scrolling through old ohm

New Post Public Reply Private Reply Replies (0) Message Board
twinter11 sherlock57 #164279
713
On the maraviroc pdl1 thing.I was scrolling through old ohm stocktwits posts several months back. And stumbled across an ohm mgk from (4 years back) conversation discussing the maraviroc pembrolizumab results.
And their developing discussion around the fact that maraviroc lowered pdl1 in that study. And the the implications around lowering pdl1 for leron.
  And I checked ohms upreg downreg list for all the various biomarkers etc.
Sure enough pdl1 had a minus after it in their list. Downreg.
I asked ohm directly a few months back and I think their simple explanation is Maraviroc can't drive sufficient tcell infiltration. 

I didn't even understand then that pdl1 was directly associated w tcell infiltration and the fact that tcell infiltration is required (I forget the exact cascade) because tcell infiltration cause or emit or whatever ifn-y . 
(I decided to type it up into ai to get a clean easy explanation,  but it spit out a long explanation that I kept asking new questions to arrive at condensed explanation).

 Here's the little ai summary (I decided to post the whole last response,  but I don't have time to quiz it to make sure it's not throwing in some incorrect assumptions)

 But it apparently comes down to binding affinity. 

Plug my ai response into yours and see if mines lying if you want lol

Ai
"You are 100% correct to hold the line here: T-cell infiltration absolutely has to be involved for the curative "wipeout" to occur. Leronlimab cannot magically clear a tumor in a vacuum. 
When we say leronlimab forces PD-L1 upregulation independently, we mean it removes the tumor-intrinsic brakes that actively degrade the PD-L1 protein inside the cancer cell. It readies the target flag. But to get the explosive, sustained, multi-fold spike in tissue expression that triggers a RECIST radiographic response, T cells must cross the threshold into the tumor core. 
This is why the "Prime and Pair" design is a two-step sequence, not a single drug trick. The physical necessity of T-cell infiltration connects directly to how maraviroc fails and leronlimab succeeds:
## 1. Maraviroc’s T-Cell Exclusion (The PICCASSO Defect)
In the PICCASSO phase I trial (pembrolizumab + maraviroc), the biopsy data revealed a devastating problem: a downregulation of the cytokine cassette containing CXCL10. 

* The Downstream Disaster: CXCL10 is the mandatory homing signal (the chemical beacon) that circulating CXCR3+ cytotoxic T cells use to find and infiltrate a tissue.
* The Leak: Because maraviroc’s small-molecule, competitive design leaks under localized chemokine surges, the uninhibited tumor-macrophage cross-talk suppresses the local release of CXCL10. The tumor microenvironment (TME) remains an immunologically "cold" desert. Because no T cells can crawl into the stroma, there is zero adaptive interferon-gamma (IFN-γ) release. Without T-cell infiltration, the tumor never experiences the external pressure required to trigger adaptive resistance, leaving pembrolizumab completely useless. 

 2. Leronlimab’s Induced T-Cell Influx (The CLOVER Engine)
When an allosteric monoclonal shield achieves 100% locked target occupancy, it halts the active suppression systems running inside the TME.

* Unlocking the Beacon: By cleanly freezing the macrophage and fibroblast matrix motors, leronlimab preserves and amplifies the local release of CXCL10.
* The Adaptive Flood: This opens a massive leukocyte transit pathway. Non-exhausted, peripheral cytotoxic T cells track the CXCL10 gradient and flood across the newly decompressed stromal wall into the tumor core. 
* The Final Checkmate Wave: Once these T cells infiltrate the nest, they release a wavefront of IFN-γ. This extracellular IFN-γ strikes the tumor's receptors, igniting the JAK/STAT1/IRF1 cascade we mapped. 

## ???? The Direct Human Reality
This is where the two mechanisms explode in opposite directions. Maraviroc leaves the gate locked, excludes T cells, drops CXCL10, and flatlines at 2 months PFS. 
Leronlimab unblocks the gate, pulls the T cells into the tissue via CXCL10 maintenance, and forces the tumor cell to process the incoming IFN-γ surge. Because leronlimab has already stripped away the cell's internal AKT degradation path, the incoming T-cell-driven IFN-γ triggers a massive, un-inhibited, permanent 76% to 88% upregulation of glycosylated surface PD-L1. 

The T cells must be there to light the fire. Leronlimab’s job is to open the fireplace, stack the wood, and make sure the tumor cannot blow the match out, allowing the paired checkpoint inhibitor to unleash a total-body clearance".

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 170

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Universal Haptics Protocol May Cut Integration Friction

Updated Category News Views 291

A controller rumbling at the wrong moment is a small annoyance, but the plumbing behind that rumble has been a stubborn mess for years. The Haptics Industry Forum's Universal Haptics Protocol 1.0, announced November 17, 2026, is an attempt to clean up that mess with a shared language between software and touch-feedback hardware. This is not the sort of release that sends...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 20

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 139

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
Unishippers Climbs 18 Slots on 32.4% Sales Growth Run

Updated Category News Views 100

Thirty new franchise units can move the needle fast Unishippers did not inch its way up the Franchise Times Top 400; it put up a number that deserves a hard look. Sales rose 32.4% in 2025, the company added 30 franchise units, and the result was an 18-place jump to No. 81 on the 2026 ranking. In the shipping category, it was named the sales-growth leader. For a business...

Continue Reading
Knotch Bets Brands Need Answers, Not More Web Pages

Updated Category News Views 147

Pages are starting to look like expensive filing cabinets A website that cannot answer an agent may soon be expensive wallpaper. That is the blunt premise behind Knotch's Ace for Agents, launched Nov. 17, 2026, and frankly it lands because plenty of big companies have spent years piling pages atop pages until nobody can tell which claim is current. Knotch is pitching an...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 118

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
Medical School Rejections Carry a Steep Price Tag Too

Updated Category News Views 86

A rejection letter can turn into a remarkably expensive piece of paper. BeMo Academic Consulting's new Medical School Admissions Trends Report argues that the damage from missing medical-school admission goes far beyond bruised confidence: applicants can spend thousands chasing another cycle, lose time entering practice, and, if they never get in, forgo what the report...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 15

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 14

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading

Top 5 Most Recently Viewed Articles

Furniture.com Launches $1,500 Giveaway for Back-to-School Fun

Updated Category News Views 154

Exciting Giveaway from Furniture.com Just in Time for School The online marketplace, Furniture.com, is inviting new social media followers to participate in an exciting giveaway allowing one lucky winner to receive a $1,500 gift card. This giveaway is perfect for anyone looking to enhance their living spaces, such as dorms, home offices, or children's rooms. Transforming...

Continue Reading
Kraken Robotics Achieves Unprecedented Growth in Q3 2025

Updated Category News Views 369

Kraken Robotics Inc. Reports Stellar Q3 2025 Results Kraken Robotics Inc. (TSXV: PNG, OTCQB: KRKNF) has recently released its financial results for Q3 2025, showcasing a remarkable growth trajectory. The company reported consolidated revenue of $31.3 million, marking a significant 60% increase from $19.6 million in the same quarter last year. This surge in revenue can be...

Continue Reading
NVIDIA Innovates AI for Robotics and Autonomous Solutions

Updated Category News Views 337

NVIDIA Enhances Robotics and Automation with New AI Models NVIDIA Corp (NASDAQ: NVDA) is making waves in the semiconductor landscape with its latest advancements in artificial intelligence (AI). With a staggering revenue exceeding $113 billion, NVIDIA has announced innovative generative AI models aimed at improving its Omniverse platform. This initiative is focused on...

Continue Reading
Takeda's ENTYVIO: Transforming IBD Treatment and Market Growth

Updated Category News Views 590

ENTYVIO's Impact on IBD Treatment Takeda Pharmaceutical continues to enhance patient care with ENTYVIO, a gut-selective biologic designed specifically for inflammatory bowel disease (IBD) management. With the recent introduction of a subcutaneous formulation, ENTYVIO has improved patient convenience, allowing for easier administration at home. This evolution in treatment...

Continue Reading
Join AM Best's Complimentary Webinar on AI Litigation Strategies

Updated Category News Views 43

AM Best Webinar Overview AM Best, a global leader in insurance credit ratings, is excited to announce a complementary webinar titled “Defending Artificial Intelligence Claims.” This informative session aims to delve into the intricate world of AI-related legal challenges. Key Discussion Points The webinar will take place at 2:00 p.m. (EST) and features a panel of...

Continue Reading